Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Novel treatment with oncolytic herpes simplex virus, 'HF10' against breast cancer].

Nihon rinsho. Japanese journal of clinical medicine - 1 May 2004

Kimata Hideto, Teshigahara Osamu, Nishiyama Yukihiro, Nakao Akimasa

Abstract excerpt

An oncolytic herpes simplex virus type 1 mutant, named HF10, has been isolated and evaluated for anti-tumor efficacy in syngeneic immuno-competent mouse models. We have found that the mutant virus can very effectively treat cancer, and that all of survived mice acquire resistance to rechallenge of the tumor cells. Since a number of studies have shown that HF10 is effective and safe for use in localized or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Models, Animal

Share to Herpesvirus 1, Human

Share to Immunotherapy

Share to Mutation

Share to Precipitin Tests

Source

Identifiers

PMID: 15148832

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Novel treatment with oncolytic herpes simplex virus, 'HF10' against breast cancer].PMID 15148832Read ↗

Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer.Semantic proximity Read ↗

Phase I Dose-escalation Clinical Trial of HF10 Oncolytic Herpes Virus in 17 Japanese Patients with Advanced Cancer.Semantic proximity Read ↗

Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy.Semantic proximity Read ↗

Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells.Semantic proximity Read ↗

The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma.Semantic proximity Read ↗

Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice.Semantic proximity Read ↗

Oncolytic herpes simplex virus vectors for cancer virotherapy.Semantic proximity Read ↗

[Development of conditionally replicating oncolytic HSV vector--targeted gene therapy for sarcoma by oncolytic viruses].Semantic proximity Read ↗

Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer.Semantic proximity Read ↗

[Progess on research of herpes simplex virus type 1 mutants for cancer therapy].Semantic proximity Read ↗

Histone Deacetylase Inhibitors Improve the Replication of Oncolytic Herpes Simplex Virus in Breast Cancer CellsSemantic proximity Read ↗

Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.